Sign In

Claudia Petritsch

Associate Professor in Research at Stanford University School of Medicine

Claudia Petritsch is an Associate Professor in Research at the Stanford University School of Medicine, specifically within the Department of Neurosurgery. Her research focuses on oligodendrocyte progenitor cells, cancer stem cells, and the intra-tumoral heterogeneity of brain tumors. She aims to understand the mechanisms behind cell fate decisions in brain progenitor cells and how these processes contribute to tumor development and treatment challenges.

Education and Career

  • PhD: Claudia earned her doctorate (Dr. rer.nat) from the Institute for Molecular Pathology (IMP) in Vienna, where she studied cancer signaling and identified key regulators of growth factor receptor kinase signaling.
  • Postdoctoral Research: She conducted postdoctoral studies at the Howard Hughes Medical Institute and the University of San Francisco, focusing on neural stem cells and asymmetric cell division.
  • Previous Positions: Before joining Stanford, she was an instructor and led a research group in Munich, Germany, where her team explored mechanisms of intracellular location for cell fate determinants.

Research Focus

Dr. Petritsch's lab investigates:

  • The intra-tumoral heterogeneity and immune suppression in brain tumors from a developmental perspective.
  • Mechanisms of cell fate decisions in both normal and malignant brain cells using patient-derived samples.
  • The development of cancer models to study glioma immune microenvironments.

Affiliations

In addition to her role at Stanford, she is a member of:

  • The Stanford Cancer Institute
  • The Wu Tsai Neurosciences Institute
  • The Maternal & Child Health Research Institute (MCHRI)

Honors

Dr. Petritsch has received several awards, including:

  • The Pediatric Cancer Model Development Award from the National Cancer Institute.
  • A Cancer Research Award from Emerson Collective.

Her work is pivotal in advancing the understanding of brain tumors, aiming to identify vulnerabilities that could be targeted therapeutically.123

Highlights

May 4 · linkedin

We are hiring! Join our excellent team effort to find cures by generating patient-derived models for childhood brain cancer - the number one cancer-related killer of children

https://lnkd.in/gpsM_69A

Apr 15 · linkedin

Our molecular case report documenting and independently validating a previously unreported fusion in desmoplastic infantile astrocytoma just got accepted in Neuro-Oncology Advances. Thank you for the wonderful teamwork, Maria Isabel Barros Guinle MD, Laura Prolo MD PhD, Jeff Nirschl MD PhD, Hannes Vogel MD, Gerry Grant MD, Kristen Yeom MD.

CDC42BPA::BRAF Represents a Novel Fusion in Desmoplastic Infantile Ganglioglioma/Astrocytoma DOI: 10.1093/noajnl/vdae050 Journal: Neuro-Oncology Advances

Related Questions

What are the main research interests of Claudia Petritsch?
How does Claudia Petritsch's work contribute to understanding brain tumors?
What are the key findings from Claudia Petritsch's studies on cancer stem cells?
What is the significance of intra-tumoral heterogeneity in brain tumors according to Claudia Petritsch?
How does Claudia Petritsch's research impact the development of new cancer treatments?
Claudia Petritsch
Claudia Petritsch, photo 1
Claudia Petritsch, photo 2
Add to my network

Location

Palo Alto, California, United States